Colonic mucosal eosinophilia and immunohistochemical expression of COX-2 and NF-kB in patients with irritable bowel syndrome

Background There is growing evidence that eosinophilic infiltration can release mediators which are harmful to the intestinal epithelium in patients with irritable bowel syndrome (IBS). Although cyclooxygenase 2 (COX-2) and nuclear factor-kappa beta (NF-kB) expression had been previously reported to increase in many inflammatory conditions, there is a paucity in data investigating their expressions in IBS. Our aim was to evaluate colonic mucosal eosinophilia and immunohistochemical expression of COX-2 and NF-kB in patients with irritable bowel syndrome. Methods A total of 80 patients who met the inclusion criteria of IBS based on Rome IV symptoms questionnaire were subjected to abdominal ultrasound, laboratory investigations, serum immunoglobulin E (IgE) level assessment and colonoscopic examination. Immunohistochemistry was performed to detect COX-2 and NF-kB expression in colonic biopsies obtained from IBS patients. Results Histopathological examination showed that 60 colonic biopsy specimens (75%) showed few mixed inflammatory cells ≤3 cells/ HPF, 12 biopsy specimens (15%) showed eosinophilic infiltration ≥25 eosinophils/HPF and 8 biopsy specimens (10%) showed severe lymphocytic infiltration and aggregation. Colonic eosinophilic infiltrate was significantly higher among patients presented with IBS-D subtype. Serum IgE was significantly higher among patients with colonic eosinophilic infiltrate than the others. In IBS-D patients, colonic mucosa showed positive expression of COX-2 and NF-kB in 52.1% and 81.25% of cases, respectively. Conclusion Patients with IBS -particularly IBS-D subtype- should undergo colonoscopy and biopsy to exclude underlying inflammatory pathology. Moreover, patients with positive COX-2 and NF-kB need further evaluation and follow-up.

[1]  F. Azpiroz,et al.  Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome , 2020, Scientific Reports.

[2]  C. Friesen,et al.  The relationship between mucosal inflammatory cells, specific symptoms, and psychological functioning in youth with irritable bowel syndrome , 2020, Scientific Reports.

[3]  Ji-yao Li,et al.  Prostaglandin E2, Produced by Mast Cells in Colon Tissues from Patients with Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice. , 2020, Gastroenterology.

[4]  Å. Keita,et al.  Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health , 2020, Inflammatory bowel diseases.

[5]  N. Mahmoud,et al.  Factors associated with irritable bowel syndrome among medical students at Ain Shams University , 2019, Journal of the Egyptian Public Health Association.

[6]  D. Schuppan,et al.  Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. , 2019, Gastroenterology.

[7]  N. Talley,et al.  Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. , 2018, The lancet. Gastroenterology & hepatology.

[8]  Lin Chang,et al.  FUNCTIONAL BOWEL DISORDERS , 2018, The American Journal of Gastroenterology.

[9]  Yan Zheng,et al.  Modulation of inflammation by toll-like receptor 4/nuclear factor-kappa B in diarrhea-predominant irritable bowel syndrome , 2017, Oncotarget.

[10]  E. Magen,et al.  Possible therapeutic role of IgE blockade in irritable bowel syndrome , 2016, World journal of gastroenterology.

[11]  Abdulhadi A. Alamodi,et al.  Irritable Bowel Syndrome: A Global Challenge Among Medical Students , 2016, Cureus.

[12]  T. Hausken,et al.  Extra-intestinal symptoms in patients with irritable bowel syndrome: related to high total IgE levels and atopic sensitization? , 2016, Scandinavian journal of gastroenterology.

[13]  S. Köklü,et al.  The Colonic Tissue Levels of TLR2, TLR4 and Nitric Oxide in Patients with Irritable Bowel Syndrome. , 2016, Internal medicine.

[14]  G. Furuta,et al.  Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. , 2015, Immunology and allergy clinics of North America.

[15]  Divyansh Bajaj,et al.  Epidemiology of Dyspepsia and Irritable Bowel Syndrome (IBS) in Medical Students of Northern India. , 2014, Journal of clinical and diagnostic research : JCDR.

[16]  S. Azzeghaiby,et al.  Expression of cyclooxygenase-2 (COX-2) in colorectal adenocarcinoma: an immunohistochemical and histopathological study. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[17]  Y. Cho,et al.  Mucosal Mast Cell Count Is Associated With Intestinal Permeability in Patients With Diarrhea Predominant Irritable Bowel Syndrome , 2013, Journal of neurogastroenterology and motility.

[18]  D. Stark,et al.  Gastrointestinal pathogen distribution in symptomatic children in Sydney, Australia , 2013, Journal of epidemiology and global health.

[19]  P. Rutgeerts,et al.  A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease , 2012, The American Journal of Gastroenterology.

[20]  D. Jewell,et al.  Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting , 2012, Scandinavian journal of gastroenterology.

[21]  W. Moon,et al.  Are Food Constituents Relevant to the Irritable Bowel Syndrome in Young Adults? - A Rome III Based Prevalence Study of the Korean Medical Students , 2011, Journal of neurogastroenterology and motility.

[22]  Hamdy Sliem,et al.  Pattern of irritable bowel syndrome and its impact on quality of life in primary health care center attendees, Suez governorate, Egypt , 2011, The Pan African medical journal.

[23]  G. Locke,et al.  Epidemiology of IBS. , 2011, Gastroenterology clinics of North America.

[24]  N. Talley,et al.  Gastrointestinal eosinophils in health, disease and functional disorders , 2010, Nature Reviews Gastroenterology &Hepatology.

[25]  L. Öhman,et al.  T-Cell Activation in Patients With Irritable Bowel Syndrome , 2009, The American Journal of Gastroenterology.

[26]  G. Barbara,et al.  Is irritable bowel syndrome an inflammatory disorder? , 2008, Current gastroenterology reports.

[27]  N. Talley,et al.  Functional gastrointestinal disorders and the potential role of eosinophils. , 2008, Gastroenterology clinics of North America.

[28]  P. Whorwell,et al.  Bloating and distention in irritable bowel syndrome: the role of visceral sensation. , 2008, Gastroenterology.

[29]  R Jones,et al.  Guidelines on the irritable bowel syndrome: mechanisms and practical management , 2007, Gut.

[30]  L. Öhman,et al.  New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[31]  E. Björnsson,et al.  Small intestinal bacterial overgrowth in patients with irritable bowel syndrome , 2006, Gut.

[32]  R. Moqbel,et al.  Differential Secretion of Cytokines , 2006, Science's STKE.

[33]  P. Venge,et al.  Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome , 2004, Gut.

[34]  B. Mckenna.  Is It Really Colitis?: Dealing With the Nearly Normal Colonic Biopsy and Variations of Microscopic Colitis , 2004 .

[35]  J. Bohr,et al.  Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients , 2004, Gut.

[36]  A. Straumann,et al.  The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract , 2004, Allergy.

[37]  A. Salas,et al.  Collagenous and Lymphocytic Colitis: Evaluation of Clinical and Histological Features, Response to Treatment, and Long-Term Follow-Up , 2003, American Journal of Gastroenterology.

[38]  D. Drossman,et al.  AGA technical review on irritable bowel syndrome. , 2002, Gastroenterology.

[39]  S. Collins.  A case for an immunological basis for irritable bowel syndrome. , 2002, Gastroenterology.

[40]  R. Simpson,et al.  COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. , 2002, Gastroenterology.

[41]  W. Chey,et al.  Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea , 2000, American Journal of Gastroenterology.

[42]  M. Neurath,et al.  Role of NF-kappaB in immune and inflammatory responses in the gut. , 1998, Gut.

[43]  D. V. van Thiel,et al.  Gastrointestinal transit: the effect of the menstrual cycle. , 1981, Gastroenterology.